{
  "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed",
  "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 52,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a process flow diagram to map clinical trials to strategic goals.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/25",
  "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed",
  "deckJsonHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed.json",
  "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.85,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Clinical trial roadmap flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6c03250-dac8-4f8f-8fed-fde06cddf513",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "Dato-DXd = datopotamab deruxtecan; NSCLC = non-small cell lung cancer; SoC = standard of care; CTx = chemotherapy; 2L = 2nd-line; 1L = 1st-line; monotx = monotherapy; 3L = 3rd-line; AGA = actionable genomic alterations; pembro = pembrolizumab; PD-L1 = programmed cell death ligand 1; carbo = carboplatin; PARP1sel = PARP1 selective; TROP2 = trophoblast cell-surface antigen 2. Collaboration partners: Daiichi Sankyo (Dato-DXd).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55bc90b6-38c8-4058-b648-986bc7b25866",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.4,
        "x": 0.53,
        "y": 0.33
      },
      "kind": "list",
      "text": "Replace current chemotherapy as monotherapy; Pursue novel combinations; Move Dato-DXd earlier in treatment paradigm; Provide evidence across spectrum of PD-L1 levels; Assess predictive value of TROP2 biomarker",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64a37db7-910a-4e1d-bb5a-f16090d914ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Potential to replace current SoC CTx in 2L+ and establish Dato-DXd as backbone in 1L",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69822176-9bd2-4d1a-9e00-220e717ce7f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Dato-DXd in NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fe51b9d-7f21-445f-b694-d2ed4d42d748",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "roadmap",
      "slug": null,
      "matchId": "04217c91-89ba-4db2-846f-bc0587bf26ce",
      "evidence": "Visual mapping of clinical trial phases to strategic objectives over time/treatment lines.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 25,
      "from": 15,
      "beatId": "ba7e7aa9-525b-4e2a-a4f1-214ecf8f098d",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 15,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "b41eaf1b-437d-4b91-9988-0e6fb0f284a8",
      "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology",
      "position": 1,
      "objective": "What are the benefits of AstraZeneca's pipeline?",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}